Fenwick represented Graybug Vision (NASDAQ: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, in its initial public offering of 5,625,000 shares of common stock at a public offering price of $16.00 per share.
The gross proceeds to Graybug Vision from the offering were approximately $90 million, before deducting underwriting discounts and commissions and other offering expenses.
SVB Leerink and Piper Sandler acted as joint bookrunning managers for the offering. Needham & Company and Wedbush PacGrow acted as passive bookrunners for the offering.
More information about the offering can be obtained from Graybug Vision’s announcement.
The Fenwick transaction team included corporate partners Robert Freedman, Effie Toshav and associates Julia Forbess, Michael Shaw, Chelsea Anderson, Steven Jean, Elliot Ginsburg, Jenna Hsieh, John Clancy, Karin Hjorth and Alyssa Zhang; as well as executive compensation & employee benefits partner Elizabeth Gartland and associate Corinne Nhaissi.